Australia markets open in 6 hours 44 minutes

Panbela Therapeutics, Inc. (PBLA)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.4150+0.0048 (+1.17%)
As of 11:45AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.99M
Enterprise value 4.61M
Trailing P/E 0.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.18

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3-99.87%
S&P500 52-week change 322.38%
52-week high 3300.0000
52-week low 30.3500
50-day moving average 30.6808
200-day moving average 314.2780

Share statistics

Avg vol (3-month) 3290.57k
Avg vol (10-day) 364.3k
Shares outstanding 54.85M
Implied shares outstanding 64.85M
Float 84.85M
% held by insiders 10.00%
% held by institutions 10.16%
Shares short (15 Feb 2024) 4106.97k
Short ratio (15 Feb 2024) 40.07
Short % of float (15 Feb 2024) 43.07%
Short % of shares outstanding (15 Feb 2024) 43.07%
Shares short (prior month 12 Jan 2024) 446.36k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 308 Nov 2017
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 318 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-191.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-34.4M
Diluted EPS (ttm)-316.5200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.58M
Total cash per share (mrq)0.53
Total debt (mrq)5.19M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.25
Book value per share (mrq)-9.81

Cash flow statement

Operating cash flow (ttm)-25.25M
Levered free cash flow (ttm)-9.86M